Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee test could end painful scope for bladder cancer checks

NCT ID NCT06310759

Diagnosis Sponsor: Tampere University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a simple urine test that looks for tumor DNA can replace the standard invasive cystoscopy (a camera inserted into the bladder) for diagnosing bladder cancer. Researchers will enroll 3,000 people who have blood in their urine and are scheduled for a cystoscopy. If the urine test proves accurate enough, it could spare many patients from an uncomfortable procedure and reduce healthcare costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
urine tumor DNA (utDNA) test
What this could lead to
If successful, this could replace many invasive cystoscopies with a simple urine test, making diagnosis easier and cheaper for patients with blood in urine.
What could go wrong
This is an observational study, not a treatment trial. The urine test may not be accurate enough to replace cystoscopy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for diagnostic cystoscopy to rule out urothelial cancer due to hematuria, imaging, or urine cytology findings.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide informed consent * Patient has been scheduled for cystoscopy to rule out urothelial cancer Exclusion Criteria: * Prior diagnosis of urothelial cancer (i.e. bladder cancer or upper tract urothelial carcinoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urothelial carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urothelial carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Helsinki University Hospital

    RECRUITING

    Helsinki, Finland

  • Jesse Brown Department Of Veterans Affairs Medical Center

    NOT_YET_RECRUITING

    Chicago, Illinois, 60612, United States

  • Kindai University Hospital

    RECRUITING

    Osaka, Japan

  • Satasairaala Hospital

    RECRUITING

    Pori, Finland

  • Seinäjoki Central Hospital

    RECRUITING

    Seinäjoki, Finland

  • Tampere University Hospital and Tampere University

    RECRUITING

    Tampere, Finland

  • Turku University Hospital

    RECRUITING

    Turku, Finland

  • Vancouver Prostate Centre

    RECRUITING

    Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.